Search
Moxidectin
go.drugbank.com/drugs/DB11431ApprovedInvestigationalVet approved[A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June 13, 2018.[L2970] … Moxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side chain at carbon 25 and a unique methoxime moiety at carbon 23.
Durlobactam
go.drugbank.com/drugs/DB16704ApprovedInvestigational[L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. … It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases.
Opium
go.drugbank.com/drugs/DB11130ApprovedIllicit[A32175] Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. … During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive.[A32171] Opium is extracted from _Papaver somniferum_, which is more known as poppies.
Mupirocin
go.drugbank.com/drugs/DB00410ApprovedInvestigationalVet approved[L10580] It is available in topical formulations only due to extensive systemic metabolism[A178531] and is used in the treatment of impetigo caused by _Staphylococcus aureus_ and _Streptococcus pyogenes … [L10580] It primarily works by inhibiting bacterial protein synthesis.
Tasimelteon
go.drugbank.com/drugs/DB09071ApprovedInvestigationalTasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010. … By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism
Tazobactam
go.drugbank.com/drugs/DB01606ApprovedInvestigationalPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections … Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms.
Entrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.
Hydromorphone
go.drugbank.com/drugs/DB00327ApprovedIllicitInvestigationalHydromorphone is a pure opioid,[A176468] a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. … [A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]
Rolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalUnlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and … By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV.
Carbidopa
go.drugbank.com/drugs/DB00190ApprovedInvestigational[L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination … therapy developed by Mayne Pharma in 1992.